Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the clinical phase I study of oxytocin in…
Iconovo to present positive data from a feasibility study on Nanofitins in ICOone
Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin based biologic drug against…
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…
Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag
Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease
Iconovo has entered into an agreement to continue the formulation development with Danish rare lung disease company Kiox Pharma. This is a continuation…
Iconovo launches improved versions of nasal ICOone inhalers
Iconovo launches improved versions of nasal ICOone. Both inhalers are designed for high technical performance and to minimize the risk of user error.…
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler
Iconovo announces that it has received an order from a company revenue wise ranking among the top ten largest pharma companies in the world to evaluate…
Iconovo to participate in the regional scale-up program 10XHEALTH
Iconovo has been invited to join the 10XHEALTH program launched by SmiLe and Medicon Village. The new 10XHEALTH program aims to provide the required skills…
Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor
Iconovo AB announce today that Gary Pitcairn will start working for the company in the role as Senior Scientific Advisor. Gary is a recognised expert…
Iconovos vd: ”Vi siktar på en affär för ICOpre under 2024”
Iconovos vd: ”Vi siktar på en affär för ICOpre under 2024”
Året 2023 påbörjades resan för Iconovo mot att bli ett lönsamt bolag. Ett ökat…
Iconovo to present at Redeye Life Science Day November 23
Johan Wäborg, CEO, will present Iconovo at Redeye Life Science Day. Learn more about why you should invest in Iconovo and get excited by our vision to…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se